Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.
The company takes another project from Taris into phase 3 as it chases a $5bn market.
The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.
